ESPR Q1 2024 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$577M

Q1 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$138M+466.1% YoY

Gross Profit

$128M92.7% margin

Operating Income

$72M52.5% margin

Net Income

$61M44.3% margin

EPS (Diluted)

$0.34

QoQ Revenue Growth

+327.1%

Cash Flow

Operating Cash Flow

$54M

Free Cash Flow

$54M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$373M

Total Liabilities

$667M

Stockholders' Equity

-$294M

Cash & Equivalents

$227M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$138M	$24M	+466.1%
Gross Profit	$128M	$13M	+907.0%
Operating Income	$72M	-$49M	+248.7%
Net Income	$61M	-$62M	+198.9%

Revenue Segments

Collaboration Revenue

$113M82%

Product

$25M18%